Results 51 to 60 of about 3,186 (203)

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

Parthenium dermatitis manifesting clinically as polymorphic light eruption and prurigo nodularis- like lesions with vasculitis-like picture on histopathology

Indian Dermatology Online Journal, 2011
Parthenium dermatitis is a widespread and distressing dermatoses in rural and urban India caused by the air borne allergen of the Compositae weed Parthenium hysterophorus.
Chembolli Lakshmi, C R Srinivas, Suma B Pillai, S Shanthakumari   +3 more
doaj   +1 more source

Psychopathology Associated with Chronic Pruritus: A Systematic Review

Acta Dermato-Venereologica, 2023
There are no previous studies of the psychopathology associated with different aetiologies of chronic pruritus. A systematic review was performed of cohort and case-control studies comparing healthy controls with patients with chronic pruritus related to
Bárbara R. Ferreira, Laurent Misery
doaj   +1 more source

The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl, Claudia Zeidler, Joyce Loewenthal, Svenja Royeck, Matthias Augustin, Robert Bissonnette, Sarina Elmariah, Brian S. Kim, Laurent Misery, Hiroyuki Murota, Hong Liang Tey, Elke Weisshaar, Gil Yosipovitch, Franz J. Legat, Adam Reich, Martin Metz, Sonja Ständer   +16 more
wiley   +1 more source

Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study [PDF]

, 2021
Jorge R. Georgakopoulos, David Croitoru, Tina Felfeli, Raed Alhusayen, Perla Lansang, Neil H. Shear, Jensen Yeung, Scott R. Walsh   +7 more
openalex   +1 more source

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer, Sarina B. Elmariah, Shawn G. Kwatra, Gil Yosipovitch, Andrew E. Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K. Jabbar‐Lopez, Liliana Ulianov, Christophe Piketty, Jonathan I. Silverberg   +10 more
wiley   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source

Effectiveness of Dupilumab for an Elderly Patient with Prurigo Nodularis Who Was Refractory and Contradicted to Traditional Therapy

Journal of Asthma and Allergy, 2021
Taoming Liu, Juan Bai, Su Wang, Shuni Ying, Sheng Li, Jianjun Qiao, Hong Fang Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaCorrespondence: Jianjun Qiao; Hong ...
Liu T, Bai J, Wang S, Ying S, Li S, Qiao J, Fang H   +6 more
doaj  

Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis

Medicines, 2020
Background: Prurigo nodularis (PN) is an intensely pruritic skin condition of considerable morbidity. However, the pathogenesis of PN and its association with underlying neuropathy is unclear.
John-Douglas Matthew Hughes, Taylor E. Woo, Micah Belzberg, Raveena Khanna, Kyle A. Williams, Madan M. Kwatra, Shahzeb Hassan, Shawn G. Kwatra   +7 more
doaj   +1 more source

Dementia Incidence in Patients With Prurigo Nodularis: An Observational Retrospective Cohort Study

JEADV Clinical Practice, EarlyView.
Madison P. Olexson, Ana Ormaza Vera, Chunghwan Ro, Clinton W. Enos   +3 more
wiley   +1 more source